Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00297661
Status:
COMPLETED
Last Update Posted:
2006-10-20
First Post:
2006-02-22
Brief Title:
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization
Sponsor:
University of Bern
Organization:
University of Bern
Study Overview
Official Title:
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization SIRTAX Trial
Status:
COMPLETED
Status Verified Date:
2006-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Context Sirolimus-eluting stents and paclitaxel-eluting stents as compared with bare-metal stents reduce the risk of restenosis It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents
Objective To determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents
Objective To determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents
Detailed Description:
Design Randomized controlled observer-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents
Patients 1012 patients undergoing percutaneous coronary intervention The two groups had similar baseline clinical and angiographic characteristics
Patients 1012 patients undergoing percutaneous coronary intervention The two groups had similar baseline clinical and angiographic characteristics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None